Goldman Sachs’s Nephros NEPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$44.2K Sell
11,908
-928
-7% -$3.7K ﹤0.01% 6449
2026
Q2
$45.8K Sell
12,836
-1,327
-9% -$4.32K ﹤0.01% 6422
2026
Q1
$42.2K Sell
14,163
-4,817
-25% -$19.2K ﹤0.01% 6308
2025
Q4
$92.6K Buy
18,980
+337
+2% +$1.72K ﹤0.01% 6200
2025
Q3
$88.2K Buy
+18,643
New +$73.2K ﹤0.01% 6099
2019
Q4
– Sell
-19,418
Closed -$156K – 5348
2019
Q3
$156K Buy
+19,418
New +$142K ﹤0.01% 4886

Other funds holding NEPH

Goldman Sachs's NEPH Position: Q3 2026 in Review

Goldman Sachs reduced its Nephros (NEPH) stake by 7.2% in Q3 2026, selling an estimated $3.7K and leaving 11,908 shares worth $44.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6449.

Goldman Sachs first reported a position in NEPH in Q3 2019 and has held it in 6 quarters since. The position peaked at $156K in Q3 2019. 36 funds tracked by Wall St. Rank hold NEPH as of Q3 2026.

  • Goldman Sachs held 11,908 shares of Nephros worth $44.2K as of Q3 2026.
  • Goldman Sachs sold 928 Nephros shares in Q3 2026, an estimated $3.7K.
  • Nephros made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #6449 holding.
  • Goldman Sachs first reported a position in Nephros in Q3 2019 and has held it in 6 quarters since.
  • Goldman Sachs's Nephros position peaked at $156K in Q3 2019.
  • 36 funds tracked by Wall St. Rank held Nephros as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.